Compugen Ltd.
CGENHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Compugen Ltd. (CGEN) is listed under Biotechnology. Valued at $183.8M, CGEN is a micro-cap name in its sector. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.
Market Cap
$183.8M
Beta
2.79
P/E (TTM)
5.11
P/E (Fwd)
-5.29
EPS (TTM)
$0.38
EPS (Fwd)
$-0.37
ROE
50.6%
ROA
15.5%
Cash
$125.3M
Total Debt
$3.0M
Free CF
$22.2M
52W Change
13.5%
Annual Financials
Cash vs Debt
Where CGEN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CGEN finished 18.26% below its 150-day moving average ($2.41) and 13.97% below its 200-day moving average ($2.29). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CGEN overbought or oversold?
At the October 20, 2026 close, CGEN's RSI(14) was 22.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $125.3M in cash comfortably exceeding the $3.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $22.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 50.6% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 15.5% further supports the picture of efficient asset utilization. Revenue has grown from $7.5M (2022) to $72.8M (2025), reflecting a 870% increase over the period.
Compugen Ltd.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, CGEN has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Compugen Ltd. and its sector.